meglumine antimoniate has been researched along with miltefosine in 52 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 13 (25.00) | 29.6817 |
2010's | 29 (55.77) | 24.3611 |
2020's | 10 (19.23) | 2.80 |
Authors | Studies |
---|---|
Arana, B; Diaz, A; Rizzo, N | 1 |
Garnier, JM; Minodier, P; Retornaz, K; Robert, S | 1 |
Mumtaz, N; Rahman, SB; ul Bari, A | 1 |
Blanc, P; Garnier, JM; Minodier, P; Noël, G; Retornaz, K; Uters, M | 1 |
Akhoundi, B; Fotouhi, A; Hooshmand, B; Kabir, MJ; Mohebali, M; Nadim, A; Rahnema, A; Razaghian, AR; Zarei, Z | 1 |
Boucher, P; Hadighi, R; Khamesipour, A; Meamar, AR; Mohebali, M; Ouellette, M; Roy, G | 1 |
Balderrama, M; Berman, JD; Rea, J; Soto, J; Soto, P; Toledo, J; Valda, L | 1 |
Ayres, DC; Giorgio, S; Pinto, LA | 1 |
Alborzi, A; Fakhar, M; Hatam, GR; Kadivar, MR; Motazedian, MH; Pouladfar, GR | 1 |
Bianciardi, P; Mateo, M; Maynard, L; Miró, G; Vischer, C | 1 |
Aresu, L; Bianciardi, P; Brovida, C; Castagnaro, M; Cavicchioli, L; Giroud, L; Valente, M; Vischer, C | 1 |
Figueroa, RA; Miranda, MC; Prager, M; Zea, DF | 1 |
Bianciardi, P; Cañavate, C; Cruz, I; Miró, G; Mortarino, M; Oliva, G; Vischer, C | 1 |
Alvar, J; Balasegaram, M; Boelaert, M; Lynen, L; Meheus, F; van Griensven, J | 1 |
López, L; Mestra, L; Rodríguez, E; Rojas, C; Sánchez, X; Vélez, I | 1 |
Chrusciak Talhari, C; Chrusciak-Talhari, A; da Silva, RM; de Oliveira Penna, G; Dietze, R; Gadelha Yamashita, EP; Lima Machado, PR; Talhari, S | 1 |
Harms, G; Reiter-Owona, I; Richter, J; Scherbaum, H; Stich, A | 1 |
de Souza, W; Godinho, JL; Rodrigues, JC; Silva, R; Simas-Rodrigues, C; Ürmenyi, TP | 1 |
Garcerant, D; Gore Saravia, N; Miranda, MC; Montero, LM; Muvdi Arenas, S; Nicholls, RS; Osorio, L; Pérez, M; Prager, M; Rodríguez-Barraquer, I; Rojas, MX; Rubiano, LC | 1 |
Castillo, H; Diaz-Toro, Y; Fernández, O; Ovalle, C; Perez, M; Saravia, NG; Valderrama, L; Valderrama, M | 1 |
Chakravarty, J; Sundar, S | 1 |
Campino, L; Henriques, S; Maia, C; Marques, M; Nunes, M; Rolão, N | 1 |
Antoniou, M; Christodoulou, V; Koutala, E; Mazeris, A; Messaritakis, I; Papadogiorgaki, S; Vlahou, A | 1 |
Blum, JA; Hatz, C; Mosimann, V; Neumayr, A | 1 |
Mesquita, JT; Reimão, JQ; Tempone, AG | 1 |
Diaz-Toro, Y; Fernández, OL; Gomez, MA; Muvdi, S; Ovalle, C; Rodríguez, I; Saravia, NG; Valderrama, L | 1 |
Barrio, A; Basombrío, MA; Cardozo, RM; Cimino, RO; de Raspi, EM; García Bustos, MF; Parada, LA; Parodi, C; Prieto, GG; Soto, J; Uncos, DA; Yeo, M | 1 |
Barrio, A; Basombrio, MA; Beckar, J; Garcia Bustos, MF; Moreno, S; Parodi, C | 1 |
Cerrone, A; Corso, R; Galiero, G; Gravino, AE; Manna, L; Muzj, P | 1 |
Fernández, OL; Gonzalez-Fajardo, L; McMahon-Pratt, D; Saravia, NG | 1 |
Aguiar, MG; de Morais-Teixeira, E; Ferreira, LA; Rabello, A; Soares de Souza Lima, B | 1 |
Caljon, G; Croft, SL; Guerin, PJ; Hendrickx, S; Maes, L | 1 |
Castro, MDM; Cossio, A; Osorio, L; Velasco, C | 1 |
Bartlett, AH; Berger, BA; Castro, MDM; Cossio, A; Pho, MT; Prada, S; Saravia, NG | 1 |
Singh, A; Sundar, S | 1 |
Cordeiro-da-Silva, A; Dantas-Torres, F; Miró, G; Travi, BL | 1 |
Castro, MDM; Cossio, A; Dávalos, D; Desai, MM; Uribe-Restrepo, A | 1 |
Fernández, OL; Gómez, MA; Martínez-Salazar, B; Regli, IB; Saravia, NG; Tacchini-Cottier, F | 1 |
Carvalho, GB; Carvalho, SH; Frézard, F; Moura, AS; Pereira, NP; Ramos, LMQC; Rocha, MOC | 1 |
Cerón, JJ; Checa, R; Daza González, MA; Fermín Rodríguez, M; Fragío Arnold, C; Martínez Subiela, S; Miró, G; Montoya, A; Portero Fuentes, M; Rupérez Noguer, C | 1 |
Barroso, DH; Freire, GSM; Gomes, CM; Martins, SS; Motta, JOCD; Paula, CDR; Pereira, LIA; Porto, C; Sampaio, RNR; Silva, JSFE | 1 |
Alipour, A; Hosseinzadeh, A; Iranpour, S | 1 |
Çavuş, İ; Harman, M; Kaya, T; Özbilgin, A; Yıldırım, A | 1 |
Alves, RB; Colombo, FA; da Silva, JC; de Freitas, RP; Gontijo, VS; Laurenti, MD; Malaquias, LCC; Marques, MJ; Nunes, JB | 1 |
Elias, VM; Osorio-Arango, K; Pinart, M; Pinzón-Flórez, CE; Reveiz, L; Romero, GA; Rueda, JR; Silveira Maia-Elkhoury, AN; Tweed, JA | 1 |
Çavuş, İ; Gündüz, C; Harman, M; Özbilgin, A; Tunalı, V; Turgay, N | 1 |
Barral-Netto, M; Carvalho, EM; Costa, B; de Jesus, DV; Doria, SS; Guerra, JO; Guerra, MDGB; Machado, PRL; Mendes, L; Ortiz, J; Penna, G; Silva, ASD; Silva, GVD | 1 |
Darchini-Maragheh, E; Goyonlo, VM; Kiafar, B; Layegh, P; Tayyebi, M | 1 |
Campos, MP; Figueiredo, FB; Gonçalves, AS; Gonçalves, G; Medeiros, LCS | 1 |
Alvarez, F; Arana, B; Boni, M; Echevarria, J; Jiménez, A; Llanos-Cuentas, A; López, L; Méndez, C; Quintero, J; Ramos, AP; Rode, J; Tabares, Y; Valencia, B; Vélez, I | 1 |
Araújo, MS; Bartholomeu, DC; Borges, VM; Cardoso, CDA; Laurenti, MD; Monte-Neto, RLD; Moreira, POL; Nogueira, PM; Rêgo, FD; Reis, AB; Soares, RP | 1 |
Broere, F; de Jong, MK; Piek, CJ; Rappoldt, A | 1 |
12 review(s) available for meglumine antimoniate and miltefosine
Article | Year |
---|---|
Chemotherapy of cutaneous leishmaniasis: a review.
Topics: Antifungal Agents; Antimony; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Ointments; Organometallic Compounds; Phosphorylcholine | 2001 |
[Visceral leishmaniasis: new drugs].
Topics: Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Child; Humans; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine | 2003 |
[Treatment of visceral leishmaniasis in children].
Topics: Amphotericin B; Antimony; Antimony Sodium Gluconate; Antiprotozoal Agents; Child; Humans; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine | 2007 |
Combination therapy for visceral leishmaniasis.
Topics: Amphotericin B; Antiprotozoal Agents; Asia; Brazil; Cost-Benefit Analysis; Drug Therapy, Combination; Europe; Humans; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine; Safety; South Africa | 2010 |
Leishmaniasis: an update of current pharmacotherapy.
Topics: Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Drug Therapy, Combination; Humans; Leishmania donovani; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Parasitic Sensitivity Tests; Paromomycin; Phosphorylcholine; Practice Guidelines as Topic; Species Specificity; Treatment Outcome | 2013 |
Evaluating drug resistance in visceral leishmaniasis: the challenges.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Resistance, Multiple; Humans; Leishmania donovani; Leishmaniasis, Visceral; Meglumine Antimoniate; Parasitic Sensitivity Tests; Phosphorylcholine; Psychodidae; Recurrence | 2018 |
Chemotherapeutics of visceral leishmaniasis: present and future developments.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Clinical Trials as Topic; Drug Resistance, Multiple; Drug Therapy, Combination; HIV Infections; Humans; India; Leishmania donovani; Leishmaniasis, Visceral; Meglumine Antimoniate; Paromomycin; Phosphorylcholine; Psychodidae; Sheep; South America; Treatment Outcome | 2018 |
Canine visceral leishmaniasis: Diagnosis and management of the reservoir living among us.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Disease Reservoirs; Dog Diseases; Dogs; Leishmania infantum; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Molecular Diagnostic Techniques; Organometallic Compounds; Phosphorylcholine; Point-of-Care Systems; Serologic Tests | 2018 |
Interventions to treat cutaneous leishmaniasis in children: A systematic review.
Topics: Antiprotozoal Agents; Clinical Trials as Topic; Humans; Leishmania; Leishmaniasis, Cutaneous; Meglumine Antimoniate; Phosphorylcholine; Rifampin | 2018 |
American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment.
Topics: Antiprotozoal Agents; Brazil; Humans; Leishmania braziliensis; Leishmania guyanensis; Leishmaniasis, Cutaneous; Meglumine Antimoniate; Patents as Topic; Phosphorylcholine | 2019 |
Efficacy of miltefosine compared with glucantime for the treatment of cutaneous leishmaniasis: a systematic review and meta-analysis.
Topics: Humans; Leishmaniasis, Cutaneous; Meglumine Antimoniate; Non-Randomized Controlled Trials as Topic; Phosphorylcholine; Randomized Controlled Trials as Topic; Treatment Outcome | 2019 |
Interventions for American cutaneous and mucocutaneous leishmaniasis.
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Azithromycin; BCG Vaccine; Female; Humans; Hyperthermia, Induced; Immunocompetence; Injections, Intramuscular; Injections, Intravenous; Interferon-gamma; Leishmaniasis Vaccines; Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous; Male; Meglumine Antimoniate; Pentoxifylline; Phosphorylcholine; Randomized Controlled Trials as Topic | 2020 |
12 trial(s) available for meglumine antimoniate and miltefosine
Article | Year |
---|---|
Miltefosine in cutaneous leishmaniasis.
Topics: Adult; Antimony; Antiprotozoal Agents; Female; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine | 2007 |
Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.
Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; Female; Humans; Iran; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine; Zoonoses | 2007 |
Efficacy of miltefosine for Bolivian cutaneous leishmaniasis.
Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; Bolivia; Child; Female; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Phosphorylcholine; Time Factors; Treatment Outcome | 2008 |
Multicentric, controlled clinical study to evaluate effectiveness and safety of miltefosine and allopurinol for canine leishmaniosis.
Topics: Allopurinol; Animals; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine | 2009 |
Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis.
Topics: Adult; Antiprotozoal Agents; Capsules; Humans; Injections, Intramuscular; Leishmania; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Military Personnel; Organometallic Compounds; Phosphorylcholine; Young Adult | 2010 |
Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil.
Topics: Adolescent; Adult; Aged; Antiprotozoal Agents; Brazil; Child; Child, Preschool; Female; Humans; Leishmania guyanensis; Leishmaniasis, Mucocutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Phosphorylcholine; Treatment Outcome; Young Adult | 2011 |
Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children.
Topics: Administration, Oral; Antiprotozoal Agents; Child; Child, Preschool; Colombia; Female; Humans; Leishmania; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine; Treatment Failure | 2012 |
[Miltefosine versus meglumine antimoniate in the treatment of mucosal leishmaniasis].
Topics: Adolescent; Adult; Aged; Antiprotozoal Agents; Comparative Effectiveness Research; Female; Humans; Injury Severity Score; Leishmaniasis, Mucocutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Nasopharynx; Organometallic Compounds; Phosphorylcholine; Young Adult | 2014 |
Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leishmania; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine; Retrospective Studies | 2015 |
A randomized, open-label clinical trial comparing the long-term effects of miltefosine and meglumine antimoniate for mucosal leishmaniasis.
Topics: Antiprotozoal Agents; Female; Humans; Leishmaniasis, Mucocutaneous; Male; Meglumine Antimoniate; Middle Aged; Phosphorylcholine; Pilot Projects; Time Factors; Treatment Outcome | 2019 |
Association of miltefosine with granulocyte and macrophage colony-stimulating factor (GM-CSF) in the treatment of cutaneous leishmaniasis in the Amazon region: A randomized and controlled trial.
Topics: Administration, Oral; Administration, Topical; Adolescent; Adult; Antiprotozoal Agents; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leishmaniasis, Cutaneous; Macrophage Colony-Stimulating Factor; Male; Meglumine Antimoniate; Middle Aged; Phosphorylcholine; Young Adult | 2021 |
A phase II multicenter randomized study to evaluate the safety and efficacy of combining thermotherapy and a short course of miltefosine for the treatment of uncomplicated cutaneous leishmaniasis in the New World.
Topics: Adult; Antiprotozoal Agents; Humans; Hyperthermia, Induced; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine; Treatment Outcome | 2022 |
28 other study(ies) available for meglumine antimoniate and miltefosine
Article | Year |
---|---|
Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs.
Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Drug Resistance; Humans; Iran; Leishmania tropica; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Parasitic Sensitivity Tests; Paromomycin; Phosphorylcholine | 2007 |
Efficacy of pentavalent antimony, amphotericin B, and miltefosine in Leishmania amazonensis-infected macrophages under normoxic and hypoxic conditions.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Cell Hypoxia; Dose-Response Relationship, Drug; Inhibitory Concentration 50; Leishmania mexicana; Macrophages, Peritoneal; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Oxygen; Phosphorylcholine | 2008 |
Isolation of Leishmania tropica from a patient with visceral leishmaniasis and disseminated cutaneous leishmaniasis, southern Iran.
Topics: Adolescent; Amphotericin B; Animals; Antiprotozoal Agents; Female; Humans; Interferon-gamma; Iran; Leishmania tropica; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine | 2008 |
Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Bone Marrow; Dog Diseases; Dogs; Female; Injections, Subcutaneous; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine | 2009 |
Administration of miltefosine and meglumine antimoniate in healthy dogs: clinicopathological evaluation of the impact on the kidneys.
Topics: Animals; Antiprotozoal Agents; Body Weight; Dogs; Female; Fluorescent Antibody Technique; Histocytochemistry; Kidney; Kidney Diseases; Kidney Tubules; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Microscopy, Electron; Organometallic Compounds; Phosphorylcholine; Random Allocation; Toxicity Tests | 2009 |
[Mucosal complication of cutaneous leishmaniasis].
Topics: Aged; Anemia; Antiprotozoal Agents; Contraindications; Eyelid Diseases; Humans; Hypertension; Kidney Failure, Chronic; Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous; Lip Diseases; Male; Meglumine; Meglumine Antimoniate; Nose Diseases; Organometallic Compounds; Phosphorylcholine | 2009 |
Treatment of imported New World cutaneous leishmaniasis in Germany.
Topics: Adolescent; Adult; Aged; Amphotericin B; Animals; Antiprotozoal Agents; Female; Germany; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Phosphorylcholine; Travel; Young Adult | 2011 |
Efficacy of miltefosine treatment in Leishmania amazonensis-infected BALB/c mice.
Topics: Animals; Antiprotozoal Agents; Azure Stains; DNA, Protozoan; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Leishmania; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Parasite Load; Phosphorylcholine; Time Factors; Ulcer | 2012 |
Novel approach to in vitro drug susceptibility assessment of clinical strains of Leishmania spp.
Topics: Antiprotozoal Agents; Cell Line; Humans; Leishmania; Leishmaniasis; Macrophages; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Parasite Load; Parasitic Sensitivity Tests; Phosphorylcholine; Temperature | 2012 |
In vitro drug susceptibility of Leishmania infantum isolated from humans and dogs.
Topics: Allopurinol; Amphotericin B; Animals; Antiprotozoal Agents; Deoxycholic Acid; Disease Reservoirs; Dog Diseases; Dogs; Drug Combinations; Humans; Immunocompetence; Immunocompromised Host; Inhibitory Concentration 50; Leishmania infantum; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Parasitic Sensitivity Tests; Phosphorylcholine | 2013 |
Drug resistance in natural isolates of Leishmania donovani s.l. promastigotes is dependent of Pgp170 expression.
Topics: Amphotericin B; Antiprotozoal Agents; Drug Resistance; Leishmania donovani; Meglumine; Meglumine Antimoniate; Membrane Proteins; Organometallic Compounds; Phosphorylcholine; Protozoan Proteins; Rhodamine 123 | 2013 |
Cutaneous leishmaniasis in Switzerland: first experience with species-specific treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiprotozoal Agents; Child; Child, Preschool; Female; Humans; Infant; Leishmania; Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Phosphorylcholine; Retrospective Studies; Species Specificity; Switzerland; Travel; Treatment Outcome; Young Adult | 2013 |
Combination therapy with nitazoxanide and amphotericin B, Glucantime®, miltefosine and sitamaquine against Leishmania (Leishmania) infantum intracellular amastigotes.
Topics: Aminoquinolines; Amphotericin B; Animals; Antiprotozoal Agents; Drug Combinations; Leishmania infantum; Leishmaniasis, Visceral; Macrophages, Peritoneal; Meglumine; Meglumine Antimoniate; Mice; Nitro Compounds; Organometallic Compounds; Parasitic Sensitivity Tests; Phosphorylcholine; Thiazoles | 2014 |
Miltefosine and antimonial drug susceptibility of Leishmania Viannia species and populations in regions of high transmission in Colombia.
Topics: Adolescent; Adult; Aged; Antimony; Child; Child, Preschool; Cohort Studies; Colombia; Drug Resistance; Humans; Infant; Leishmania; Leishmaniasis; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Phosphorylcholine; Randomized Controlled Trials as Topic; Young Adult | 2014 |
In vivo antileishmanial efficacy of miltefosine against Leishmania (Leishmania) amazonensis.
Topics: Animals; Antiprotozoal Agents; Leishmania mexicana; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Mice; Organometallic Compounds; Phosphorylcholine; Spleen | 2014 |
Ex vivo host and parasite response to antileishmanial drugs and immunomodulators.
Topics: Adolescent; Animals; Antiprotozoal Agents; Female; Humans; Immunologic Factors; Interferon-alpha; Interleukin-10; Interleukin-13; Leishmania; Leishmaniasis; Leukocytes, Mononuclear; Macrophages; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine; Tumor Necrosis Factor-alpha; Young Adult | 2015 |
Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.
Topics: Administration, Oral; Administration, Topical; Animals; Antiprotozoal Agents; Appointments and Schedules; Disease Models, Animal; Drug Therapy, Combination; Injections, Intramuscular; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Mesocricetus; Organometallic Compounds; Paromomycin; Phosphorylcholine; Skin; Spleen; Treatment Outcome | 2015 |
Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study.
Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Child, Preschool; Cohort Studies; Colombia; Female; Humans; Leishmania; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Phosphorylcholine; Risk Factors; Treatment Failure; Young Adult | 2017 |
Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis.
Topics: Administration, Oral; Antiprotozoal Agents; Caregivers; Child; Child, Preschool; Cost-Benefit Analysis; Directly Observed Therapy; Drug Costs; Female; Humans; Injections, Intramuscular; Leishmania; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Monte Carlo Method; Organometallic Compounds; Phosphorylcholine; Sensitivity and Specificity; Treatment Outcome; United States | 2017 |
Resistance of
Topics: Animals; Antiprotozoal Agents; Cells, Cultured; Drug Resistance; Extracellular Traps; Humans; Leishmania guyanensis; Leishmaniasis, Cutaneous; Meglumine Antimoniate; Mice; Mice, Inbred C57BL; Neutrophils; Parasitic Sensitivity Tests; Phosphorylcholine; Primary Cell Culture; Reactive Oxygen Species | 2018 |
Effect of two treatments on changes in serum acute phase protein concentrations in dogs with clinical leishmaniosis.
Topics: Acute-Phase Proteins; Allopurinol; Animals; Antiprotozoal Agents; Aryldialkylphosphatase; Dog Diseases; Dogs; Leishmania infantum; Leishmaniasis, Visceral; Meglumine Antimoniate; Phosphorylcholine | 2019 |
Comparison of
Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Drug Resistance; Female; Genotyping Techniques; Humans; Leishmania; Leishmaniasis, Cutaneous; Male; Meglumine Antimoniate; Paromomycin; Phosphorylcholine; Real-Time Polymerase Chain Reaction; Turkey | 2020 |
LEISHMANICIDAL ACTIVITY in vivo OF A MILTEFOSINE DERIVATIVE IN Mesocricetus auratus.
Topics: Animals; Antiprotozoal Agents; Cricetinae; Cytokines; Leishmania infantum; Leishmaniasis, Visceral; Male; Meglumine Antimoniate; Mesocricetus; Phosphorylcholine; Spleen | 2020 |
Overcoming the Challenge; In Vivo Efficacy of Miltefosine for Chronic Cutaneous Leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Male; Meglumine Antimoniate; Mice; Phosphorylcholine | 2021 |
The effect of oral miltefosine in treatment of antimoniate resistant anthroponotic cutaneous leishmaniasis: An uncontrolled clinical trial.
Topics: Administration, Oral; Adolescent; Adult; Antiprotozoal Agents; Child; Child, Preschool; Drug Resistance; Female; Humans; Leishmaniasis, Cutaneous; Male; Meglumine Antimoniate; Middle Aged; Phosphorylcholine; Young Adult | 2021 |
Increased Leishmania infantum resistance to miltefosine and amphotericin B after treatment of a dog with miltefosine and allopurinol.
Topics: Allopurinol; Amphotericin B; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Resistance; Female; Leishmania infantum; Leishmaniasis, Visceral; Meglumine Antimoniate; Phosphorylcholine | 2021 |
Leishmania amazonensis from distinct clinical forms/hosts has polymorphisms in Lipophosphoglycans, displays variations in immunomodulatory properties and, susceptibility to antileishmanial drugs.
Topics: Amphotericin B; Animals; Dogs; Glycosphingolipids; Interleukin-6; Leishmania; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Phosphorylcholine; Tumor Necrosis Factor-alpha | 2022 |
Survival time and prognostic factors in canine leishmaniosis in a non-endemic country treated with a two-phase protocol including initial allopurinol monotherapy.
Topics: Allopurinol; Animals; Creatinine; Dog Diseases; Dogs; Humans; Leishmania infantum; Leishmaniasis; Leishmaniasis, Visceral; Meglumine Antimoniate; Prognosis; Recurrence; Urea | 2023 |